Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Columbus, Ohio

4 studies are recruiting for non-small cell lung cancer (nsclc) in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University, Columbus, Ohio

   Locations

   15 in total

   Run by

   Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

   See if you can join NCT05985655 on ClinicalTrials.gov

2. A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

   The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 0045, Columbus, Ohio

   Locations

   17 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06476808 on ClinicalTrials.gov

3. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

   This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University, Columbus, Ohio

   Locations

   38 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06026410 on ClinicalTrials.gov

4. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov